Combined treatment with bevacizumab and 5-Fluorouracil attenuates the postoperative scarring response after experimental glaucoma filtration surgery

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 2, 2010, Pages 928-932

  How, Alicia ^a   Chua, Jocelyn Leng Leng ^a   Charlton, Amanda ^b   Su, Roseline ^c   Lim, Marcus ^a   Kumar, Rajesh S ^c   Crowston, Jonathan G ^d   Wong, Tina T ^c  

^a SINGAPORE NATIONAL EYE CENTRE   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; COLLAGEN TYPE 1; FIBRONECTIN; FLUOROURACIL; MESSENGER RNA; PHOSPHATE BUFFERED SALINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC ANTIMETABOLITE; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLAGEN METABOLISM; COMBINATION CHEMOTHERAPY; CONJUNCTIVA DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; EXPERIMENTAL RABBIT; EYE PHOTOGRAPHY; FILTERING OPERATION; HISTOPATHOLOGY; MONOTHERAPY; NONHUMAN; OCULAR BLOOD VESSEL; OCULAR FIBROSIS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE SCARRING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCAR FORMATION; SURVIVAL TIME; ANIMAL; CONJUNCTIVA; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; FEMALE; FIBROSIS; GENETICS; METABOLISM; PATHOLOGY; RABBIT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCAR; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; CICATRIX; COLLAGEN TYPE I; CONJUNCTIVA; DRUG THERAPY, COMBINATION; FEMALE; FIBRONECTINS; FIBROSIS; FILTERING SURGERY; FLUOROURACIL; POSTOPERATIVE COMPLICATIONS; RABBITS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 77449156623     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-3949     Document Type: Article

References (35)

1. Nissen NN, Polverini PJ, Koch AE, Volin MV, Gamelli RL, DiPietro LA. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol. 1998;152(6):1445-1452.
2. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002; 20(21):4368-4380.
3. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(21):2805-2816.
4. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342.
5. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10(2):145-147.
6. Corpechot C, Barbu V, Wendum D, et al. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology. 2002;35(5): 1010-1021.
7. Wilgus TA, Ferreira AM, Oberyszyn TM, Bergdall VK, Dipietro LA. Regulation of scar formation by vascular endothelial growth factor. Lab Invest. 2008;88(6):579-590.
8. Yoshiji H, Kuriyama S, Yoshii J, et al. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut. 2003;52(9):1347-1354.
9. Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ. Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol. 2001;12(7):1448-1457.
10. August DA, Serrano D, Poplin E. "Spontaneous, " delayed colon and rectal anastomotic complications associated with bevacizumab therapy. J Surg Oncol. 2008;97(2):180-185.
11. Reddick R, Merritt JC, Ross G, Avery A, Peiffer RL. Myofibroblasts in filtration operations. Ann Ophthalmol. 1985;17(3):200-203.
12. Mastropasqua L, Carpineto P, Ciancaglini M, Zuppardi E, Lobefalo L, Gallenga PE. Delayed post-operative use of 5-fluorouracil as an adjunct in medically uncontrolled open angle glaucoma. Eye. 1998;12(Pt 4):701-706.
13. Wong TT, Khaw PT, Aung T, et al. The Singapore 5-Fluorouracil trabeculectomy study: effects on intraocular pressure control and disease progression at 3 years. Ophthalmology. 2009;116(2):175-184.
14. Higginbotham EJ, Stevens RK, Musch DC, et al. Bleb-related endophthalmitis after trabeculectomy with mitomycin C. Ophthalmology. 1996;103(4):650-656.
15. Greenfield DS, Suner IJ, Miller MP, Kangas TA, Palmberg PF, Flynn HW Jr. Endophthalmitis after filtering surgery with mitomycin. Arch Ophthalmol. 1996;114(8):943-949.
16. Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging. 2006;37(2):144-146.
17. Grewal DS, Jain R, Kumar H, Grewal SP. Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy: a pilot study. Ophthalmology. 2008;115(12):2141-2145.
18. Memarzadeh F, Varma R, Lin LT, et al. Post-operative use of bevacizumab as an anti-fibrotic agent in glaucoma filtration surgery in the rabbit. Invest Ophthalmol Vis Sci. 2009;50(7):3233-3237.
19. Cordeiro MF, Gay JA, Khaw PT. Human anti-transforming growth factor-beta2 antibody: a new glaucoma anti-scarring agent. Invest Ophthalmol Vis Sci. 1999;40(10):2225-2234.
20. Wells AP, Crowston JG, Marks J, et al. A pilot study of a system for grading of drainage blebs after glaucoma surgery. J Glaucoma. 2004;13(6):454-460.
21. Shah M, Foreman DM, Ferguson MW. Neutralising antibody to TGF-beta 1,2 reduces cutaneous scarring in adult rodents. J Cell Sci. 1994;107(Pt 5):1137-1157.
22. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest. 2004;113(7): 1040-1050.
23. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res. 2006;312(5):549-560.
24. Cao Y, Linden P, Farnebo J, et al. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci U S A. 1998;95(24):14389-14394.
25. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003; 9(6):653-660.
26. Lee KS, Park SJ, Kim SR, et al. Inhibition of VEGF blocks TGF-beta1 production through a PI3K/Akt signalling pathway. Eur Respir J. 2008;31(3):523-531.
27. Li ZD, Bork JP, Krueger B, et al. VEGF induces proliferation, migration, and TGF-beta1 expression in mouse glomerular endothelial cells via mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Biochem Biophys Res Commun. 2005;334(4): 1049-1060.
28. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480-1487.
29. Hu DN, Ritch R, Liebmann J, Liu Y, Cheng B, Hu MS. Vascular endothelial growth factor is increased in aqueous humor of glaucomatous eyes. J Glaucoma. 2002;11(5):406-410.
30. Sakaguchi H, Takai S, Sakaguchi M, et al. Chymase and angiotensin converting enzyme activities in a hamster model of glaucoma filtering surgery. Curr Eye Res. 2002;24(5):325-331.
31. Honjo M, Tanihara H, Kameda T, Kawaji T, Yoshimura N, Araie M. Potential role of Rho-associated protein kinase inhibitor Y-27632 in glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2007; 48(12):5549-5557.
32. The Fluorouracil Filtering Surgery Study Group. Fluorouracil Filtering Surgery Study one-year follow-up. Am J Ophthalmol. 1989; 108(6):625-635.
33. Kitazawa Y, Kawase K, Matsushita H, Minobe M. Trabeculectomy with mitomycin. A comparative study with fluorouracil. Arch Ophthalmol. 1991;109(12):1693-1698.
34. Skuta GL, Beeson CC, Higginbotham EJ, et al. Intraoperative mitomycin versus postoperative 5-fluorouracil in high-risk glaucoma filtering surgery. Ophthalmology. 1992;99(3):438-444.
35. Kitnarong N, Chindasub P, Metheetrairut A. Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma. Adv Ther. 2008;25(5):438-443.